MARATTO

article · Egyptian Journal of Dermatology and Venerology

Regulation of angiogenesis and inflammatory pathways by glycyrrhizic acid

20241 citationOpen accessUniversity of Sadat City

Abstract

Skin cancer accounts for most malignancies across the globe. They are primarily divided into melanoma and nonmelanoma skin malignancies. Nonmelanoma skin cancer includes basal cell carcinoma and squamous cell carcinoma. Glycyrrhetinic acid (GA) is a bioactive compound extracted from licorice that exhibits an inhibition effect on various cancers. GA has been reported to have in vitro cytotoxic effects on several human cancer cells. However, reports on the mode of action and detailed mechanism of GA in vitro in skin cancer disease are limited. Hence, GA’s effect on the human skin cell line BJ and MCC13 was investigated. MTT assay showed that GA had cytotoxic effects on MCC13 cells but was non-toxic to the normal cells of BJ in a time-dose dependent manner. GA also inhibited the angiogenic sprouting of new blood vessels in tumor progression. In gene expression assay, GA induces mitochondrial apoptosis through the induction and inhibition of Cytochrome C and Bcl2 respectively. In conclusion, GA is a potent candidate to induce apoptosis and concurrently inhibit the invasion, migration, and angiogenesis of the MCC13 cell line through increasing TNF-alpha concentration resulting in the necroptotic pathway induction.

Research topics

  • Pharmacological Effects of Natural Compounds
  • Chromatography in Natural Products
  • Phytochemistry and biological activity of medicinal plants

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.4103/ejdv.ejdv_39_23

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.